1. Home
  2. ANET vs NVO Comparison

ANET vs NVO Comparison

Compare ANET & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arista Networks Inc.

ANET

Arista Networks Inc.

HOLD

Current Price

$130.01

Market Cap

168.2B

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$62.22

Market Cap

212.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANET
NVO
Founded
2004
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
168.2B
212.7B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
ANET
NVO
Price
$130.01
$62.22
Analyst Decision
Strong Buy
Hold
Analyst Count
15
10
Target Price
$163.93
$54.25
AVG Volume (30 Days)
6.7M
19.2M
Earning Date
02-17-2026
02-04-2026
Dividend Yield
N/A
2.15%
EPS Growth
26.15
10.06
EPS
2.63
3.67
Revenue
$8,448,346,000.00
$49,580,393,058.00
Revenue This Year
$29.46
$7.25
Revenue Next Year
$21.86
$0.24
P/E Ratio
$49.66
$15.58
Revenue Growth
27.75
16.64
52 Week Low
$59.43
$43.08
52 Week High
$164.94
$93.80

Technical Indicators

Market Signals
Indicator
ANET
NVO
Relative Strength Index (RSI) 50.40 72.64
Support Level $120.00 $56.29
Resistance Level $133.34 $60.63
Average True Range (ATR) 4.67 1.44
MACD -0.02 0.59
Stochastic Oscillator 46.10 96.28

Price Performance

Historical Comparison
ANET
NVO

About ANET Arista Networks Inc.

Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: